List view / Grid view
4 August 2014 | By Boehringer Ingelheim & Zealand Pharma
Zealand Pharma and Boehringer Ingelheim jointly announced a new global exclusive licence, research and development collaboration...
28 July 2014 | By AstraZeneca
AstraZeneca announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291...
25 July 2014 | By Gilead
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing Authorization Application for Zydelig®...
24 July 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead’s investigational drug tenofovir alafenamide...
22 July 2014 | By AstraZeneca
AstraZeneca announced that MedImmune has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies...
21 July 2014 | By Teva
...opens door to a strong and novel migraine prevention and treatment franchise within its CNS portfolio.
18 July 2014 | By Amgen
Analysis shows study met primary and all secondary endpoints AMG 416 is a novel calcimimetic administered intravenously...
17 July 2014 | By Roche
Roche presented data from two phase II studies investigating whether crenezumab can delay cognitive and functional decline in people with mild-to-moderate Alzheimer’s disease...
17 July 2014 | By Pfizer
Pfizer Inc. and InnoPharma, Inc. announced that they have entered into an agreement under which Pfizer will acquire InnoPharma...
16 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease...
15 July 2014 | By Mundipharma EDO GmbH
Mundipharma EDO GmbH is pleased to announce strong preclinical activity in Multiple Myeloma with its lead small molecule compound EDO-S101...
9 July 2014 | By Boehringer Ingelheim
Results from a Phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia aged 65 or older and ineligible for intensive remission induction therapy, lived longer...
9 July 2014 | By Domainex
Domainex Ltd announced that its lead compound has demonstrated a more potent effect in a key model of chronic obstructive pulmonary disease than either roflumulast or a p38 inhibitor...
9 July 2014 | By Fraunhofer IME
The operative business of European ScreeningPort GmbH has been integrated into the Fraunhofer Institute for Molecular Biology and Applied Ecology IME located in Aachen...
7 July 2014 | By Myriad RBM
Collaboration will focus on development of novel diagnostic tests for dialysis patients...
